Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy of Afatinib in the clinical practice - First results of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Wolfgang Brueckl

Citation

Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292

Authors

W.M. Brueckl1, E. Laack2, M. Reck3, F. Griesinger4, H. Schäfer5, C. Kortsik6, T. Gaska7, J. Rawluk8, S. Krüger9, K. Kokowski10, S. Budweiser11, A. Schueler12, S. Kiessling12

Author affiliations

  • 1 Dept. Of Internal Medicine 3, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, 90419 - Nuremberg/DE
  • 2 Hemato-oncology, Hamburg, Hamburg/DE
  • 3 Airway Research Center North, German Center For Lung Research,, LungenClinic Grosshansdorf, 22927 - Grosshansdorf/DE
  • 4 Dept. Of Hematology And Oncology, Pius Hospital, 26121 - Oldenburg/DE
  • 5 Department Of Pneumology, SHG-Clinic, Voelklingen/DE
  • 6 Dept. Of Pneumology, KKM St.Hildegardis Krankenhaus, 55131 - Mainz/DE
  • 7 Hematology And Oncology, Bruederkrankenhaus St. Josef, 33098 - Paderborn/DE
  • 8 Klinik Für Innere Medizin I, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, 79106 - Freiburg/DE
  • 9 Dept. Pulmonology, Florence-Nightingale-Hospital, Düsseldorf/DE
  • 10 Dept. Of Pneumology, Krankenhaus München Bogenhausen Med. II Abteilung, 81925 - Munich/DE
  • 11 Department Of Internal Medicine Iii, Division Of Pulmonary And Respiratory Medicine, RoMed Clinical Centre, Rosenheim/DE
  • 12 Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany, 55216 - Ingelheim am Rhein/DE
More

Resources

Background

Afatinib is an irreversible ErbB family blocker, which is approved as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. Here we report the first interim analysis of the NIS GIDEON, which was initiated to investigate the efficacy and tolerability of Afatinib in first line treatment in the daily clinical routine in Germany.

Methods

EGFR-mutated NSCLC patients were treated with Afatinib according to label until progression, death or discontinuation due to patients’ or physicians’ decision. Efficacy (objective response rate, ORR; disease control rate, DCR and progression-free survival, PFS) was prospectively assessed by investigators and additional data about tolerability under everyday treatment conditions were documented.

Results

A total of 151 pat. were enrolled in the study and received Afatinib treatment. EGFR mutations comprised exon 19 deletions (Del19, 56.6 %), L858R point mutations (21.9 %) and uncommon mutations (18.5 %). Median age was 67 years (38-89) with 91 Pat. ≥65 years (60.3%). Pat. started treatment on 40mg/d (72.8 %) Afatinib or < 40mg/d (25.8 %). Dose reductions during the course of therapy were frequent, 61.8 % with 40mg/d starting dose and 53.8% with <40mg/d. ORR for the total treated population was 73% with a DCR of 90 %. ORR was similar according to different subgroups, e.g. mutation type and age. mPFS at the time of analysis was 12.9 Mon. and in the group of pat. ≥65 years 13.7 Mon. OS date are not mature yet. The most frequent documented AEs were diarrhea and rash/acne, with 11.6 % of pat. discontinued treatment due to drug related AEs.

Conclusions

Afatinib is a standard therapy for patients with activating EGFR mutations in Germany. The first results of this prospective NIS confirm the robust clinical data for Afatinib in the clinical routine setting, especially in the elderly population, which is underrepresented in clinical trials. A starting dose of < 40 mg Afatinib in selected pat. does not seem to be inferior in terms of efficacy.

Clinical trial identification

NCT02047903.

Legal entity responsible for the study

Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.

Funding

Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.

Editorial Acknowledgement

Disclosure

W.M. Brueckl: Payments for membership on advisory boards: Boehringer Ingelheim. M. Reck: Honoraria for lectures and consultancy: Hoffmann-La Roche, Lilly, Boehringer Ingelheim, Abbot, AstraZeneca, Celgene, BMS, MSD, Merck, Novartis and Pfizer. S. Krüger: Honoraria, Advisory boards and lectures: Boehringer Ingelheim. A. Schueler, S. Kiessling: Employee: Boehringer Ingelheim Pharma GmbH & Co. KG. All other authors have declared no conflicts of interest.

Resources from the same session

VSV-IFN_-NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Presenter: Steven Powell

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).

Presenter: Cinta Hierro

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings